Pills, capsules, and tablets may not be the most efficient method for administering medicines as only ~10 – 30 per cent of the drug reaches the bloodstream. Several factors, including food effect, enzymatic degradation and first-pass metabolism are responsible for the low absorption rate of medicines that are administered as solid-dose forms.
Australia-based drug delivery company SUDA Pharmaceuticals Ltd (ASX:SUD) has stepped ahead in the evolution of drug delivery technology, increasing the bioavailability of the drug from 10 – 30 per cent to as high as 95 per cent through its unique platform technology - OroMist®.
SUDA is developing low-risk oral sprays using its OroMist® technology to reformulate existing billion-dollar pharmaceuticals. The Company is targeting large markets, including insomnia ($4 billion by 2026), migraine ($9 billion by 2026), medical grade cannabis ($66 billion by 2025) and cancer ($424 billion for solid tumours by 2027).
Reformulating Anagrelide to Treat Cancer
To target the large cancer market for solid tumours, the Company is formulating a generic drug Anagrelide to treat a rare blood disorder where a patient’s platelet count is too high.
Research to date has demonstrated that Anagrelide lowers the elevated platelet count, which is a favourable step as research shows that a high platelet count plays a crucial role in the metastatic spread and growth of cancerous tumours. SUDA’s researchers are investigating the platelets’ role in cancer and the potential use of anagrelide drug as a treatment to target platelets.
Currently, newer cancer treatments comprise immunotherapy that induces cancer patients’ immune system. SUDA’s Anagrelide could complement these treatments, rendering circulating cancer cells more vulnerable to attack by the body’s own “killer” T cells and could thus offer a beneficial new adjunctive therapy.
Moreover, the potential application of Anagrelide across a wide array of solid tumours makes it an attractive proposal for the Company.
SUDA is in the process of developing Anagrelide as an oro-mucosal spray formulation in order to minimise the risk of cardiac side effects, which are greater with standard oral doses.
Additionally, the Company also owns intellectual property for Anagrelide: Prevention and treatment of metastatic disease in thrombocytotic cancer patients.
Before understanding how Anagrelide will support in cancer treatment, let us look into the relationship between platelet count and cancer progression.
Relation Between Platelet Count and Cancer Progression
In addition to playing a crucial role in wound healing and controlling the clotting process, platelets have been found to play an active role in several processes supporting cancer. Platelets release different bio-active materials in the bloodstream when they are activated by the cancer cells, in order to support the primary tumour generate its own blood supply and further protect the released cancer cells that move in the body to form new tumours.
Comprehending the importance of platelets in supporting their growth, the cancer cells release chemicals into the body to generate more platelets, which puts the overall survival of the cancer patient at risk. Medical and Science experts believe that platelet reduction can improve the outcomes for cancer patients.
It is worth mentioning that SUDA’s Anagrelide plays a considerable role in lowering platelets without impacting any other blood cells.
How Anagrelide can Help in Cancer Treatment?
Anagrelide may assist to reduce tumour growth by slowing the production of platelets, which will further expose the cancer cells to the immune system. By potentially decelerating the growth of the tumours, the existing cancer drugs will then have a greater chance of reducing the tumour burden.
Notably, anagrelide is proposed as a neo-adjuvant or adjuvant therapy to support cutting edge treatments
In the case of an adjuvant therapy, anagrelide will possibly play a role in lowering platelet numbers, consequently reducing the levels of platelet-derived growth drivers that enable tumours to grow, become established and metastasise.
In addition, in case of neo-adjuvant therapy, which permits other anti-cancer agents or drugs to act more efficiently, anagrelide will possibly play a role in lowering the number of platelets available to protect circulating tumour cells and safeguard them from killer T-cells of the immune system.
Project Director for Anagrelide Project – Dr Richard Franklin
SUDA appointed a new Project Director, Dr Richard Franklin, for the development of Anagrelide last year. Dr Franklin holds more than 40 years of experience in pharmaceutical research and development with previous roles at Glaxo, Sterling Winthrop, Shire Pharmaceuticals, Wyeth and AstraZeneca.
Importantly, Dr Franklin was involved in the development and registration of Anagrelide for the treatment of essential thrombocythemia in Europe. Dr Franklin is a member of SUDA’s Scientific Advisory Board.
SUDA is well on track to develop Anagrelide as an oro-mucosal spray formulation, which is expected to limit unwanted side effects of the drug. The Company is making considerable progress to develop Anagrelide towards Phase I clinical trials.
SUD last traded at $0.047.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.